Crispr Therapeutics AG (NASDAQ:CRSP) has received a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.
Brokers have set a 12 month consensus target price of $25.83 for the company and are predicting that the company will post ($0.49) EPS for the current quarter, according to Zacks. Zacks has also assigned Crispr Therapeutics AG an industry rank of 154 out of 265 based on the ratings given to its competitors.
A number of research analysts have recently issued reports on CRSP shares. Chardan Capital started coverage on Crispr Therapeutics AG in a research report on Monday, March 27th. They set a “buy” rating and a $23.50 target price on the stock. Piper Jaffray Companies set a $21.00 target price on Crispr Therapeutics AG and gave the company a “buy” rating in a research report on Thursday, February 16th.
Shares of Crispr Therapeutics AG (NASDAQ:CRSP) traded up 1.25% during trading on Thursday, reaching $17.00. 48,358 shares of the company’s stock traded hands. The company has a 50 day moving average price of $18.29 and a 200-day moving average price of $19.09. The stock’s market cap is $676.77 million. Crispr Therapeutics AG has a one year low of $11.63 and a one year high of $25.00.
Crispr Therapeutics AG (NASDAQ:CRSP) last announced its earnings results on Thursday, May 11th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.06. The business had revenue of $2.70 million for the quarter. On average, equities research analysts expect that Crispr Therapeutics AG will post ($2.45) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Crispr Therapeutics AG (CRSP) Given $25.83 Average Target Price by Brokerages” was published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://sportsperspectives.com/2017/05/24/crispr-therapeutics-ag-crsp-given-25-83-average-target-price-by-brokerages-updated.html.
In other Crispr Therapeutics AG news, CEO Rodger Novak sold 50,000 shares of the firm’s stock in a transaction on Thursday, April 20th. The stock was sold at an average price of $17.88, for a total value of $894,000.00. Following the transaction, the chief executive officer now owns 1,262,711 shares in the company, valued at approximately $22,577,272.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Samarth Kulkarni sold 11,615 shares of the firm’s stock in a transaction on Tuesday, April 25th. The shares were sold at an average price of $16.78, for a total value of $194,899.70. Following the completion of the transaction, the insider now owns 137,047 shares in the company, valued at approximately $2,299,648.66. The disclosure for this sale can be found here. Insiders sold a total of 148,912 shares of company stock worth $2,539,480 in the last 90 days.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Clough Capital Partners L P bought a new stake in shares of Crispr Therapeutics AG during the fourth quarter worth about $16,676,000. Franklin Resources Inc. bought a new stake in shares of Crispr Therapeutics AG during the fourth quarter worth about $14,389,000. New Leaf Venture Partners L.L.C. bought a new stake in shares of Crispr Therapeutics AG during the fourth quarter worth about $11,882,000. Orbimed Advisors LLC bought a new stake in shares of Crispr Therapeutics AG during the fourth quarter worth about $7,541,000. Finally, Novo A S bought a new stake in shares of Crispr Therapeutics AG during the fourth quarter worth about $4,524,000. Institutional investors own 0.01% of the company’s stock.
Crispr Therapeutics AG Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.